67 results
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
26 Jul 24
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
4:05pm
President and Chief Medical Officer Mitchell Glass, M.D. “Excess TNF-α in the blood or tissue can lead to diseases and disorders marked by acute or chronic … that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being
8-K
EX-99.2
TNFA
TNF Pharmaceuticals Inc.
26 Jul 24
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
4:05pm
that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being … developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
17 Jun 24
Entry into a Material Definitive Agreement
9:04am
stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling … cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform
8-K
EX-99.1
TNFA
TNF Pharmaceuticals Inc.
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
reducing chronic inflammatory markers in patients treated with MYMD-1. MYMD-1 holds potential to be the first drug approved by the FDA for sarcopenia … on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell
8-K
EX-99.1
wo3jzru2pl
5 Mar 24
Regulation FD Disclosure
11:00am
8-K
EX-99.1
osp19 hyga2b4wx
13 Feb 24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
4:57pm
8-K
EX-99.1
66h0v8dvsva819ts4
6 Dec 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
vzlbve18d9luxw8 psse
19 Oct 23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
9:00am
8-K
EX-99.1
0cysr 87awvj2b9buw
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
8-K
EX-99.1
jdf1 3s6j3
14 Aug 23
Regulation FD Disclosure
8:30am
8-K
px54g 78qrob10etx48c
3 Aug 23
MyMD Pharmaceuticals Phase 2 Trial Update
4:30pm
8-K
EX-99.1
7441r9llc0rae2w
3 Aug 23
MyMD Pharmaceuticals Phase 2 Trial Update
4:30pm
8-K
7jzqo5 y3nljsq8ycg
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am
8-K
EX-99.1
s61c l1xhte
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am